BioCentury
ARTICLE | Clinical News

Marinus' anticonvulsive fails in Phase III

June 14, 2016 1:14 AM UTC

Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) sank $3.72 (70%) to $1.62 after its ganaxolone ( CCD-1042) missed the primary endpoint in a 359-patient Phase III study as an adjunctive treatment of drug-resistant focal onset seizures. Marinus said it will discontinue ganaxolone's development in the indication.

Ganaxolone did not significantly reduce the frequency of focal onset seizures from baseline vs. placebo (21.3% reduction vs. 10.3%, p=0.1537). ...